Innoviva - 21 Year Stock Split History | INVA

Stock split history for Innoviva since 2004. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Innoviva Annual Stock Splits
Innoviva Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.136B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $783.103B 63.53
Johnson & Johnson (JNJ) United States $399.649B 16.60
AbbVie (ABBV) United States $370.636B 20.70
Novo Nordisk (NVO) Denmark $311.614B 21.11
Roche Holding AG (RHHBY) Switzerland $262.452B 0.00
Novartis AG (NVS) Switzerland $227.865B 14.27
Merck (MRK) United States $226.737B 11.75
Pfizer (PFE) United States $143.715B 8.15
Sanofi (SNY) $140.749B 13.33
Bayer (BAYRY) Germany $23.657B 4.39